---
title: "NEOVOLTA INC C/WTS 01/04/2027 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 2.014 M"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/239634547.md"
datetime: "2025-05-09T20:32:30.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/239634547.md)
  - [en](https://longbridge.com/en/news/239634547.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/239634547.md)
generator: "portal-rs"
---

# NEOVOLTA INC C/WTS 01/04/2027 (TO PUR COM) | 10-Q: FY2025 Q3 Revenue: USD 2.014 M

Revenue: As of FY2025 Q3, the actual value is USD 2.014 M.

EPS: As of FY2025 Q3, the actual value is USD -0.04.

### Segment Revenue

-   Revenues from contracts with customers for the three months ended March 31, 2025 were $2,014,105 compared to $283,900 for the three months ended March 31, 2024.
-   Revenues for the nine months ended March 31, 2025 were $3,675,922 compared to $2,065,858 for the nine months ended March 31, 2024.

### Operational Metrics

-   Gross profit for the three months ended March 31, 2025 was $514,508 compared to $166,145 for the three months ended March 31, 2024.
-   Gross profit for the nine months ended March 31, 2025 was $931,266 compared to $493,190 for the nine months ended March 31, 2024.
-   Net loss for the three months ended March 31, 2025 was - $1,449,331 compared to - $589,473 for the three months ended March 31, 2024.
-   Net loss for the nine months ended March 31, 2025 was - $3,384,962 compared to - $1,574,232 for the nine months ended March 31, 2024.

### Cash Flow

-   Net cash flows used in operating activities for the nine months ended March 31, 2025 were - $3,501,515 compared to - $988,827 for the nine months ended March 31, 2024.
-   Net cash flows provided by financing activities for the nine months ended March 31, 2025 were $3,051,054 compared to zero for the nine months ended March 31, 2024.

### Unique Metrics

-   General and administrative expenses for the three months ended March 31, 2025 were $1,857,531 compared to $756,118 for the three months ended March 31, 2024.
-   General and administrative expenses for the nine months ended March 31, 2025 were $4,136,167 compared to $2,085,976 for the nine months ended March 31, 2024.

### Future Outlook and Strategy

-   The company anticipates that demand for its products will ultimately increase over time and, in conjunction with its recently obtained line of credit and the completion of its February 2025 private offering, it will have sufficient cash to operate for at least the next 12 months.
-   The company is monitoring international developments in Ukraine and Israel but does not believe they will significantly impact domestic markets or international supply chains for its product components.

### Related Stocks

- [NEOVW.US](https://longbridge.com/en/quote/NEOVW.US.md)

## Related News & Research

- [Nvidia Just Delivered Bad News for AMD and Intel](https://longbridge.com/en/news/297432140.md)
- [Has Novo Nordisk Finally Found the Catalyst That Could Flip the Script on Eli Lilly?](https://longbridge.com/en/news/297409652.md)
- [Frontline Earnings Call: Record Profits Amid Mounting Risks](https://longbridge.com/en/news/297410743.md)
- [Equitable Holdings Inc. Takes Position in TechnipFMC plc $FTI](https://longbridge.com/en/news/297418121.md)
- [Corient Private Wealth LP Purchases New Position in Halozyme Therapeutics, Inc. $HALO](https://longbridge.com/en/news/297417752.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**